Cumberland Pharmaceuticals And Pernix Therapeutics Enter Into Exclusive Agreement To Promote Omeclamox-Pak®

   Cumberland Pharmaceuticals And Pernix Therapeutics Enter Into Exclusive
                     Agreement To Promote Omeclamox-Pak®

- New triple therapy product for H. pylori

- Cumberland responsible for gastroenterologist promotion

- Pernix responsible for primary care promotion

PR Newswire

NASHVILLE, Tenn. and THE WOODLANDS, Texas, Oct. 28, 2013

NASHVILLE, Tenn. and THE WOODLANDS, Texas, Oct. 28, 2013 /PRNewswire/
--Cumberland Pharmaceuticals Inc.  (NASDAQ:CPIX) and Pernix Therapeutics, LLC
(NYSE: PTX) today announced an agreement for the promotion of Omeclamox-Pak
covering the United States.

Omeclamox-Pak^® is a branded prescription product that combines omeprazole,
amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H.
pylori) infection and duodenal ulcer disease. It is the first FDA approved
triple combination medication to contain omeprazole as the proton pump
inhibitor and is prescribed over a shortened treatment period of ten days.

Under the terms of the agreement, Cumberland will promote the product to
gastroenterologists across the United States through its field sales force
which also promotes its Kristalose brand. Pernix will promote the product
through its specialty sales force focusing on select primary care physicians.
The companies will cooperate in the marketing and other activities needed to
support the commercialization of the brand.

"We have been searching for an FDA approved gastroenterology product that can
be featured by our field sales force," said A.J. Kazimi, Chief Executive
Officer of Cumberland Pharmaceuticals. "We have been very selective in the
brands that we bring into our portfolio, and believe that Omeclamox-Pak is an
excellent fit for our field sales organization. We look forward to featuring
this important product to caregivers and their patients suffering from ulcers
caused by h. pylori infections."

Dr. Brian Fennerty, M.D. Professor of Medicine, Division of Gastroenterology
at Oregon Health & Science University said, "Published studies show that a
single ten-day regimen of twice-daily therapy with omeprazole, amoxicillin and
clarithromycin eradicates 80 to 90 percent of H. pylori infections."

"Gastroenterologists are the leading prescribers of h. pylori treatments and
we are excited to partner with Cumberland to reach that key audience for the
Omeclamox-Pak brand," said Cooper Collins, Chief Strategic Officer of Pernix
Therapeutics. "We believe that together we should be able to build a great
brand from the strong existing foundation that has been created by the Pernix
sales team."

About Omeclamox-Pak^®

Omeprazole is an antisecretory drug, which works by decreasing the amount of
acid the stomach produces. Clarithromycin and amoxicillin are antibacterial
drugs, which inhibit the growth of bacteria allowing the stomach lining to
heal. Omeclamox-Pak is contraindicated in patients with a history of
hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The
safety and effectiveness of Omeclamox-Pak in the pediatric population has not
yet been established. Omeclamox-Pak was approved by the U.S. Food and Drug
Administration in 2011.

About Helicobacter pylori

H. pylori is a bacterium acquired largely by people living in developing
countries. Researchers suspect the bacteria are passed through contact with
human saliva and waste, or contaminated food and water. If H. pylori is left
untreated, it can damage the stomach and small intestine wall causing peptic
ulcer disease, specifically duodenal ulcers. Symptoms of H. pylori-induced
duodenal ulcers generally surface in adults and may include burning pain in
the abdomen, nausea, vomiting, bloating, and weight loss. Nearly two-thirds of
the world population is infected with H. pylori, including 50 percent of
adults older than age 60 and 20 percent of adults under 40 years old.

About Duodenal Ulcers

Despite common belief, healthcare providers do not attribute the cause of
duodenal ulcers to stress, alcohol consumption or spicy foods, though all can
further inflame the small intestine wall. Patients with duodenal ulcers caused
by H. pylori can be diagnosed through a series of simple tests, including
blood, urea breath and stool antigen sampling. Other more invasive procedures
can include both an upper gastrointestinal (GI) series and endoscopy. Patients
who suffer severe abdominal pains, or blood in stool or vomit, may have ulcers
which perforated the duodenal wall.

About Pernix Therapeutics LLC

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on
the sales, marketing, and development of branded, generic and OTC
pharmaceutical products. The Company manages a port-folio of branded and
generic products. The Company's branded products for the pediatrics market
include CEDAX^®, an antibiotic for middle ear infections, NATROBA^™, a topical
treatment for head lice marketed under an exclusive co-promotion agreement
with ParaPRO, LLC, a family of prescription treatments for cough and cold
(BROVEX^®, ALDEX^® and PEDIATEX^®). The Company's branded products for
gastroenterology include OMECLAMOX-PAK^®, a 10-day treatment for H. pylori
infection and duodenal ulcer disease, and REZYST^™, a probiotic blend to
promote dietary management. The Company promotes its branded pediatric and
gastroenterology products through its sales force. Pernix markets its generic
products through its wholly-owned subsidiary, Macoven Pharmaceuticals. A
product candidate utilizing cough-related intellectual property is in
development for the U.S. OTC market. Founded in 1996, the Company is based in
The Woodlands, TX.

Additional information about Pernix is available on the Company's website
located at www.pernixtx.com.

About Cumberland Pharmaceuticals Inc.

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical
company focused on the acquisition, development and commercialization of
branded prescription products. The Company's primary target markets include
hospital acute care and gastroenterology. Cumberland's product portfolio
includes Acetadote^® (acetylcysteine) Injection for the treatment of
acetaminophen poisoning; Caldolor^® (ibuprofen) Injection, the first
injectable treatment for pain and fever available in the United States; and
Kristalose^® (lactulose) for Oral Solution, a prescription laxative.
Cumberland is dedicated to providing innovative products which improve quality
of care for patients.

For more information, please visit the company website at
www.cumberlandpharma.com.

Important Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, which are subject to
certain risks and reflect Cumberland's current views on future events based on
what it believes are reasonable assumptions. No assurance can be given that
these events will occur. As with any business, all phases of Cumberland's
operations are subject to factors outside of its control, and any one or
combination of these factors could materially affect Cumberland's results of
operations. These factors include market conditions, competition, an inability
of manufacturers to produce Cumberland's products on a timely basis or failure
of manufacturers to comply with regulations applicable to pharmaceutical
manufacturers, maintaining an effective sales and marketing infrastructure and
other factors discussed in the Company's most recent Form 10-K and subsequent
10-Q's as filed with the SEC. There can be no assurance that results
anticipated by the Company will be realized or that they will have the
expected effects. Readers are cautioned not to place undue reliance on
forward-looking statements, which speak only as of the date hereof. The
Company does not undertake any obligation to publicly revise these statements
to reflect events after the date hereof.

SOURCE Cumberland Pharmaceuticals Inc.

Website: http://www.cumberlandpharma.com
Contact: Investors: Elizabeth Davis, Cumberland Pharmaceuticals, 615-255-0068,
investors@cumberlandpharma.com, PernixTherapeutics Holdings, Inc. Michael C.
Pearce, President and Chief Executive Officer, 800-793-2145 ext.
1501mpearce@pernixtx.com or Media: Rebecca Kirkham, Lovell Communications,
615-297-7766, rebecca@lovell.com
 
Press spacebar to pause and continue. Press esc to stop.